To evaluate the safety and effectiveness of the TaurusTrio™ Heart Valve System in a patient population with symptomatic severe AR requiring replacement/repair of their native aortic valve that are at high risk for open surgical aortic valve replacement/repair (SAVR).
Patients who voluntarily participate and sign the informed consent and are able to comply with the entire trial process;
Age ≥ 18 years;
Jet width ≥ 65% of LVOT
Vena contracta width of > 6 mm
Congenital uni- or bicuspid aortic valve morphology；
Previous prosthetic aortic valve (bioprosthesis or mechanical) implant；
Mitral regurgitation or Tricuspid regurgitation> moderate；
Clinically significant coronary artery disease (CAD) requiring revascularization within 30 days prior to index procedure, or planned CAD revascularization procedure within 12 months after index procedure；
Peijia Medical Technology (Suzhou) Co., Ltd.
Lead sponsor